Sunshine Biopharma Inc. (SBFM-NASDAQ)

Sunshine Biopharma Inc.
6500 Trans-Canada Highway, 4^th floor
Pointe-Claire, Quebec
H9R 0A5, Canada
Phone: (514) 426-6161
https://sunshinebiopharma.com 

Sunshine Biopharma Inc. (“Sunshine Biopharma” or “the Company”) is a revenue-generating pharmaceutical company offering life-saving medicines within a variety of therapeutic areas, including oncology and antivirals. The Company’s proprietary therapeutic drug development program includes three product candidates: (1) Adva-27a, a small chemotherapy molecule for pancreatic cancer, (2) K1.1, a messenger RNA (mRNA) therapeutic for liver cancer, and (3) SBFM-PL4, a PLpro inhibitor for the treatment of COVID-19. Sunshine Biopharma’s proprietary pharmaceutical pipeline addresses large markets with significant unmet needs in oncology and anti-viral indications, creating a diversified portfolio with a combined market potential of over $30 billion for the initial targeted indications. In addition to its proprietary drug development efforts, the Company also operates two wholly-owned subsidiaries: Nora Pharma Inc., a Canadian corporation with a portfolio of over 50 generic prescription drugs; and Sunshine Biopharma Canada Inc., a Canadian corporation, which sells over-the-counter (OTC) supplements. According to the Company, the growth of its revenue-generating generic pharmaceutical business, through the operations of Nora Pharma, places Sunshine Biopharma on track to achieve profitability by FY 2025, with the generated cash flow expected to support and facilitate the development of its proprietary pharmaceutical pipeline. Sunshine Biopharma’s revenue generating generic pharmaceutical business, in conjunction with its focused proprietary drug development efforts, provides a low-risk model where the lengthy pharmaceutical development and approval process is supported by revenue generating activities.

* The Corporate Snapshot was last updated on October 27, 2023.